Next Article in Journal
Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic
Previous Article in Journal
Primary Epithelioid Angiosarcoma of the Breast Masquerading as Carcinoma
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer

1
hope Research Centre, Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
2
Department of Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, ON K1Y 4K7, Canada
3
Sanofi–Aventis Canada, Laval, QC, Canada
4
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
*
Author to whom correspondence should be addressed.
Received: 7 November 2009 / Revised: 11 December 2009 / Accepted: 9 January 2010 / Published: 1 February 2010
Background: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (TAC) compared with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) following primary surgery for breast cancer in women with operable, axillary lymph node–positive breast cancer. Methods: A Markov model looking at two time phases—5-year treatment and long-term follow-up—was constructed. Clinical events included clinical response (based on disease-free survival and overall survival) and rates of febrile neutropenia, stomatitis, diarrhea, and infections. Health states were “no recurrence,” “locoregional recurrence,” “distant recurrence,” and “death.” Costs were based on published sources and are presented in 2006 Canadian dollars. Model inputs included chemotherapy drug acquisition costs, chemotherapy administration costs, relapse and follow-up costs, costs for management of adverse events, and costs for granulocyte colony-stimulating factor (G-CSF) prophylaxis. A 5% discount rate was applied to costs and outcomes alike. Health utilities were obtained from published sources. Results: For TAC as compared with FAC, the incremental cost was $6921 per life-year (LY) gained and $6,848 per quality-adjusted life-year (QALY) gained. The model was robust to changes in input variables (for example, febrile neutropenia rate, utility). When G-CSF and antibiotics were given prophylactically before every cycle, the incremental ratios increased to $13,183 and $13,044 respectively. Conclusions: Compared with FAC, TAC offered improved response at a higher cost. The cost-effectiveness ratios were low, indicating good economic value in the adjuvant setting of node-positive breast cancer patients.
Keywords: adjuvant chemotherapy; breast cancer; cost analysis; economic model; prophylaxis adjuvant chemotherapy; breast cancer; cost analysis; economic model; prophylaxis
MDPI and ACS Style

Mittmann, N.; Verma, S.; Koo, M.; Alloul, K.; Trudeau, M. Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer. Curr. Oncol. 2010, 17, 7-16. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.445

AMA Style

Mittmann N, Verma S, Koo M, Alloul K, Trudeau M. Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer. Current Oncology. 2010; 17(1):7-16. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.445

Chicago/Turabian Style

Mittmann, N., S. Verma, M. Koo, K. Alloul, and M. Trudeau 2010. "Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer" Current Oncology 17, no. 1: 7-16. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.445

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop